Suppr超能文献

载脂蛋白E基因型不影响阿尔茨海默病的认知衰退速率。

Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease.

作者信息

Growdon J H, Locascio J J, Corkin S, Gomez-Isla T, Hyman B T

机构信息

Department of Neurology, Massachusetts General Hospital, Boston, USA.

出版信息

Neurology. 1996 Aug;47(2):444-8. doi: 10.1212/wnl.47.2.444.

Abstract

BACKGROUND

Inheritance of the apolipoprotein E (apoE) epsilon 4 allele is a risk factor for developing Alzheimer's disease (AD) and is associated with a lower age of dementia onset. The purpose of this study was to determine whether apoE genotypes differentially influence the course of cognitive decline in AD dementia.

METHODS

We administered nine cognitive tests that assessed explicit memory, attention, language, visuospatial function, frontal-lobe function, and logical reasoning abilities to 66 probable AD patients every 6 to 24 months over a span of up to 5.5 years. We identified apoE genotype by a PCR-based method; there were 16 patients with epsilon 3/3, 34 with epsilon 3/4, and 16 with epsilon 4/4. Using regression statistical methods, we computed the change in performance for each test for each patient over time. We then analyzed the mean change in each test in patients grouped according to apoE genotype.

RESULTS

For the AD patients as a group, performance on all cognitive tests declined significantly over time, but the rate of decline did not vary significantly across apoE genotypes on any cognitive test. Specifically, the rate of cognitive decline was not faster in patients with an epsilon 4 allele than in those with epsilon 3/3.

CONCLUSIONS

These results indicate that the mechanism placing individuals with an epsilon 4 allele at risk for developing AD does not influence the rate of cognitive decline. These observations imply that the influence of apoE epsilon 4 either precedes or occurs at an early point in the AD disease process.

摘要

背景

载脂蛋白E(apoE)ε4等位基因的遗传是患阿尔茨海默病(AD)的一个风险因素,并且与痴呆发病年龄较低相关。本研究的目的是确定apoE基因型是否对AD痴呆患者认知衰退的进程有不同影响。

方法

我们对66例很可能患有AD的患者,在长达5.5年的时间里,每6至24个月进行九项认知测试,这些测试评估了外显记忆、注意力、语言、视觉空间功能、额叶功能和逻辑推理能力。我们通过基于聚合酶链反应的方法确定apoE基因型;有16例患者为ε3/3,34例为ε3/4,16例为ε4/4。使用回归统计方法,我们计算了每位患者每项测试随时间的表现变化。然后我们分析了根据apoE基因型分组的患者每项测试的平均变化。

结果

作为一个整体的AD患者,所有认知测试的表现随时间显著下降,但在任何认知测试中,apoE基因型之间的下降速率没有显著差异。具体而言,携带ε4等位基因的患者认知衰退速率并不比携带ε3/3的患者更快。

结论

这些结果表明,使携带ε4等位基因的个体有患AD风险的机制并不影响认知衰退速率。这些观察结果意味着apoEε4的影响要么在AD疾病进程中先于发病出现,要么在发病早期就已发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验